A novel topical gel, HT-001, has shown potential as a treatment for cutaneous side effects from epidermal growth factor ...
Progressing first-in-class, tissue-tethered autoimmune platform – Type 1 diabetes candidate on track for CTA submission in 2025; first universal candidate targeting CD1a initially for atopic ...
Researchers investigate the cellular and molecular mechanisms through which stress exacerbates immunoglobulin E cutaneous allergic inflammation.
Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR ) and its oncology-focused subsidiary, Citius Oncology (Nasdaq: CTOR ), today announced significant progress in ...
Anifrolumab by AstraZeneca for Subacute Cutaneous Lupus Erythematosus (SCLE): Likelihood of Approval
According to GlobalData, Phase III drugs for Subacute Cutaneous Lupus Erythematosus (SCLE ... It is a fully human monoclonal antibody. It targets IFN-alpha receptor subunit 1 (IFNAR1). The drug ...
Research Center for Environmental Quality Management, Graduate School of Engineering, Kyoto University, Otsu, Shiga 520-0811, Japan Key Laboratory of Industrial Ecology and Environmental Engineering ...
Davis R Ingram; Lloye M Dillon; Dina Chelouche Lev; Alexander Lazar; Elizabeth G Demicco; Burton L Eisenberg; Todd W Miller ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback